Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 0.40 |
| ▸ | APP | P05067 | 8/20 | 0.40 |
| ▸ | BACE2 | Q9Y5Z0 | 8/20 | 0.40 |
| ▸ | PLAU | P00749 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14720961 | 0.87 | BACE1 (0.42) | BACE1APPBACE2PLAUMEN1 | |
| SCHEMBL10322066 | 0.86 | BACE1 (0.43) | BACE1APPBACE2PLAUMEN1 | |
| SCHEMBL10321286 | 0.83 | L3MBTL1 (0.50) | BACE1APPBACE2MEN1KMT2A | |
| SCHEMBL14720590 | 0.83 | BACE1 (0.43) | BACE1APPBACE2PLAUMEN1 | |
| SCHEMBL14720653 | 0.81 | BACE1 (0.41) | BACE1APPBACE2PLAUMEN1 | |
| SCHEMBL8516151 | 0.80 | BACE1 (0.43) | BACE1APPBACE2CTSDSIRT6 | |
| SCHEMBL10325119 | 0.80 | POLB (0.35) | BACE1PLAUMEN1KMT2A | |
| SCHEMBL360918 | 0.79 | SIRT6 (0.47) | BACE1PLAUSIRT6 | |
| SCHEMBL14720953 | 0.78 | PLAU (0.32) | BACE1APPBACE2PLAUMEN1 | |
| SCHEMBL10325550 | 0.75 | NNMT (0.43) | BACE1PLAUMEN1KMT2AAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3023423-B1 | 2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS | NOVARTIS AG (CH) | 2017-05-31 | — | — | EP | claimed |
| EP-3023423-A1 | 2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS | Novartis AG (CH) | 2016-05-25 | — | — | EP | claimed |
| US-9163011-B2 | Oxazine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-10-20 | — | — | US | claimed |
| US-20150150877-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | claimed |
| EP-2748162-A1 | 2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS | Novartis AG (CH) | 2014-07-02 | — | — | EP | claimed |
| US-20130172331-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG | 2013-07-04 | — | — | US | claimed |
| WO-2013027188-A1 | 2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS | NOVARTIS AG (CH) | 2013-02-28 | — | — | WO | claimed |
| EP-3023423-B1 | 2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS | NOVARTIS AG (CH) | 2017-05-31 | — | — | EP | disclosed |
| EP-3023423-A1 | 2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-9163011-B2 | Oxazine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-10-20 | — | — | US | disclosed |
| US-20150150877-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| EP-2748162-A1 | 2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS | Novartis AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-20130172331-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG | 2013-07-04 | — | — | US | disclosed |
| WO-2013027188-A1 | 2 -AMINO-4 - (PYRIDIN- 2 -YL) - 5, 6 -DIHYDRO-4H- 1, 3 -OXAZINE DERIVATIVES AND THEIR USE AS BACE-1 AND/OR BACE - 2 INHIBITORS | NOVARTIS AG (CH) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172331-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BACE2, BACE1, PSEN1 | BACE1 2/4885APP 5/4885BACE2 1/4885 |
| US-20150150877-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BACE2, BACE1, PSEN1 | BACE1 2/4885APP 5/4885BACE2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.